Insider · SEC Form 4 filer

Donald Williams

Companies

Where they file as an insider

Palisade Bio (PALI) Director Latest filing Oct 2, 2026

Track record

Did their buys beat the typical stock?

Open-market buys6
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check1

Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.

Palisade Bio (PALI) Bought Oct 1–2, 2026 · $28.8K · 20,000 shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
Palisade Bio (PALI) Bought Jan 9–16, 2026 · $17.8K · 10,000 shares Behind typical Mar 31, 2026 $1.75 → Sep 30, 2026 $1.35 · −22.9% (typical stock +1.7%)
Palisade Bio (PALI) Bought May 28, 2024 · $4.86K · 1,000 shares Behind typical Jun 30, 2024 $4.50 → Dec 31, 2024 $1.65 · −63.3% (typical stock +3.9%)
Palisade Bio (PALI) Bought Jan 31, 2024 · $6.1K · 10,000 shares Not counted Not counted. We have no fund price for this stock on both Mar 31, 2024 and Sep 30, 2024.

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist